Bristol Myers Squibb and Nektar Therapeutics ended their global clinical program for a potential bladder cancer and renal cell carcinoma treatment, causing the latter's shares to drop over 24% to $4.68 per share on Thursday.
The decision was mutual and was based on disappointing results from analyses of two late-stage trials combining bempegaldesleukin with Opdivo to treat the said cancers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,